Pathways in Rare Disease

Served as an advisor or consultant for: Intrabio LtdHas disclosed the following relevant financial relationships:Served as a speaker or a member of a speakers bureau for: Amgen; Alexion; Ultragenyx

Received grants for clinical research from: Amgen; Alexion; Ascendis; Chugai; Radius; Takeda; UltragenyxServed as an advisor or consultant for: Abbvie; Aria Pharmaceuticals, Inc.; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Chiesi; CSL Behring, DevPro, GlaxoSmithKline; IQVIA; Novartis; Polarean; ProterixBio, Inc.

Served as a speaker or a member of a speakers bureau for: AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; United Therapeutics Received grants for clinical research from: AstraZeneca; Bayer; Biogen; Chiesi; Gilead; GlaxoSmithKline; Merck; Nitto BioPharma; Patara/Respivant; Regeneron Pharmaceuticals; Roche; SanofiHas disclosed the following relevant financial relationships:Received grants for clinical research from: Greenwich Biosciences; Encoded; StokeServed as an advisor or consultant for: Bayer; Biotest; Chugai; CSL Behring; Novo Nordisk; Octapharma; Pfizer; Roche; SOBI;...

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Pathways in Rare Disease📍 RareDiseaseDay is on February 28. Watch this video to understand a patient's journey with pustular psoriasis. raredisease MedEd LightUpForRare 🖥️ Earn credit by learning more about rare diseases:
Source: Medscape - 🏆 386. / 55 Read more »

Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease - Nature MedicineA novel multi-omics workflow, combining gut microbiome metagenomics, metatranscriptomics and metabolomics, enabled the identification of the microbial pathways responsible for the degradation of the immunomodulatory drug 5-ASA in the gut of patients with inflammatory bowel disease.
Source: NatureMedicine - 🏆 451. / 53 Read more »

New Hope for Treatment of Rare Metabolic Brain DiseaseScientists reveal the results of a controlled clinical trial for a new drug to treat X-linked adrenoleukodystrophy. X-ALD is the most prevalent of the approximately 50 rare diseases that affect the white matter of the brain, referred to as leukodystrophies. The genetic damage in X-ALD is due to a d
Source: SciTechDaily1 - 🏆 84. / 68 Read more »

Changes in Alzheimer's Pathology Don't Match Clinical TrendsWhile recent studies have suggested a decrease in the incidence of clinical dementia in the US, there does not seem to have been a corresponding reduction in neurodegenerative pathologies, a new study shows. NeuroTwitter
Source: Medscape - 🏆 386. / 55 Read more »